eBay Inc vs Novartis AG — how do they compare? eBay Inc trades at $112.83 (market cap $50.07B), while Novartis AG trades at $151.1 (market cap $287.66B). The key difference: Novartis AG is far larger — about 5.7× eBay Inc's market cap, and Novartis AG pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| EBAY | NVS | |
|---|---|---|
Market Cap | $50.07B | $287.66B |
Volume | 5,186,418 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $118.96 | $168.62 |
52-Week Low | $76.79 | $113.50 |
Enterprise Value | $53.41B | $327.68B |
Dividend Yield | 1.1% | 3.14% |
Signals from Pluang's Aura AI — not financial advice
EBAY trades at $112.54, down 2.22% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters with Q1 2026 EPS of $1.66 beating expectations of $1.58. Revenue growth accelerated to $11.1B in 2025, while maintaining robust profitability with 71.79% gross margins and 17.61% net income margin. Recent developments include the UK regulator clearing eBay's acquisition of Depop and ongoing market speculation about GameStop's takeover interest.
EBAY presents a mixed investment case with strong fundamentals offset by acquisition uncertainty. The stock trades above analyst consensus target of $108.78 despite recent weakness. Key opportunities include continued earnings momentum and advertising revenue growth, while risks center on competitive pressures and potential takeover volatility. Institutional sentiment remains cautiously optimistic with 46% buy ratings.
Novartis (NVS) trades at $150.36, down 1.96% with bearish technical signals. The company maintains strong profitability with 75.38% gross margins and 23.92% net income margin, though recent earnings show mixed results with one beat and two misses. Recent acquisitions including Myricx Bio for up to $1.5 billion expand the oncology pipeline, while regulatory approvals for Itvisma and positive drug trial data support growth prospects.
While analyst consensus leans cautious with 68% hold ratings, Novartis' robust cash flow generation and strategic pipeline investments provide long-term value. Key risks include execution challenges from recent acquisitions and competitive pressures in pharmaceuticals. The stock offers stability through strong fundamentals but faces near-term technical headwinds.
Trailing returns across standard periods
Latest headlines on both assets
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →